Search

Objective To evaluate the accuracy of bioelectrical impedance analysis (BIA) in measurement of appendicular skeletal muscle mass (ASM) of adults. Methods A total of 836 adults aged 18-42 years were recruited in Guangzhou using a convenient sampling method from April 2021 to September 2022. ASM was measured using BIA and Dual-energy X-ray absorptiometry (DXA). Using DXA as the standard method, the consistency between the BIA and DXA measurements was evaluated by intra-class correlation coefficients (ICCs) and Bland-Altman analysis in logarithmically transformed data, in order to evaluate the accuracy of BIA in ASM measurement. Receiver operating characteristic curve was plotted to evaluate the diagnostic value of BIA for screening low muscle mass. Results A total of 774 individuals were included for analysis finally. ICCs for ASM measured by BIA and DXA were 0.774 and 0.667 in males and females, respectively. Mean ratios (limits of Agreement) of ASM were 0.94 (0.80-1.10) and 0.91 (0.78-1.05) in males and females, respectively. Area under curve of BIA for screening low muscle mass were 0.91 and 0.94 in males and females, respectively. The optimal cut-off values of Z-score by BIA for males and females were -0.57 and -0.66, respectively. Sensitivity and specificity for males were 82.5% and 86.0%, while being 86.8% and 93.8%, for females. Conclusion BIA shows a moderate consistency with DXA for measuring ASM in adults. Furthermore, BIA yields a good diagnostic value in identifying low muscle mass in adults aged 18-42 years. [ABSTRACT FROM AUTHOR]

The purpose of the study is to construct recombinant goat pox virus (GPV) expressing Peste des petits ruminants virus (PPRV) H protein, and to evaluate the immunization effect. Recombinant GPV containing PPRV H gene (rGPV-PPRV-H) was selected and purified by gpt and eGFP utilizing plaque purification, and the final selected recombinant GPV was proved to be purified by PCR. Immunofluorescence and Western blotting showed that the recombinant virus could express H protein of PPRV while infecting lamb testis cells. Six goats were immunized with 2 x 10(6) PFU rGPV-PPRV-H through intradermal injection, and were immunized for the second time at 28 days with the same dose recombinant virus after first immunization. Serum was collected after immunization, and was analyzed for the neutralization antibodies. 21 days after first immunization, the neutralization antibodies of GPV were 40, 80, > or = 80, > or = 80, 40, > or = 80 in turn, and neutralization antibodies of PPRV were 80, 80, 80, 80, 40, 40, 10 in turn; 14 days after second immunization, the neutralization antibodies of GPV were all > or = 80, and the neutralization antibodies of PPRV were > 80, 80, > 80, 80, 80 and 40 in turn. This study established a foundation for the industrialization of the PPRV recombinant GPV vaccine.

Equine interferon-gamma (eIFN-gamma) expressed both in E. coli and baculovirus were evaluated for antiviral activity against recombinant Vesicular Stomatits Virus expressing green fluorescence protein (rVSV-GFP) in EFK-78 cells. The assays were conducted in 96-well plate. Virus infectivity was measured by quantifying GFP-positive cells, instead of quantifying the CPE reduction. Prior to infection of EFK-78 cells with rVSV-GFP, the cells were incubated with eIFN-gamma. The GFP expression in the EFK-78 cells dramatically decreased in the cells treated with eIFN-gamma in a dose-dependent manner, comparing with the mock-treated cells. The titers of antiviral activity were 1 x 10(3) AU/mL and 1 x 10(5) AU/mL of eIFN-gamma expressed from E. coli and baculovirus, respectively. The antiviral activities of the recombinant eIFN-gamma were highly efficient and specific, as it was blocked by mAbs against eIFN-gamma.